Dzugaeva Khava B.

KRAS-targeted therapy in oncology: From four decades of failed attempts to a new era of precision medicine

A narrative review critically evaluates the biological basis of KRAS oncogenesis, the pharmacological obstacles that delayed drug development, the clinical performance and limitations of approved inhibitors, resistance mechanisms and rational combination strategies, and the evidence base and uncertainties surrounding next-generation therapeutic approaches.